Amyotropic Lateral Sclerosis (ALS) clinical trials at UCSF

8 in progress, 3 open to eligible people

Amyotropic lateral sclerosis (ALS) is a disease that damages nerve cells in the brain and spinal cord. UCSF is testing the safety of a new drug for ALS. They are also studying how brain signals can be used to control devices and observing brain changes in people with certain brain disorders.

Showing trials for

  • ECoG BMI for Motor and Speech Control

    open to eligible people ages 21 years and up

    Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.

    San Francisco, California

  • PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

    open to eligible people ages 18-80

    This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.

    San Francisco, California and other locations

  • ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

    open to eligible people ages 18 years and up

    ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

    San Francisco, California and other locations

  • RAPA-501 Therapy for ALS Expanded Access Protocol

    Sorry, not accepting new patients

    RAPA-501-ALS is an Intermediate-Size Expanded Access Trial of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

    San Francisco, California and other locations

  • Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

    Sorry, in progress, not accepting new patients

    A Phase 2 open label study evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.

    San Francisco, California and other locations

  • TPN-101 in Patients With C9ORF72 ALS/FTD

    Sorry, in progress, not accepting new patients

    This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD).

    San Francisco, California and other locations

  • HEALEY ALS Platform Trial - Master Protocol

    Sorry, in progress, not accepting new patients

    The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

    San Francisco, California and other locations

  • Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)

    Sorry, in progress, not accepting new patients

    REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be investigated.

    San Francisco, California and other locations

Our lead scientists for Amyotropic Lateral Sclerosis (ALS) research studies include .

Last updated: